https://doi.org/10.4081/hmr.v1i8.280

Anti-CD80 monoclonal antibody: galiximab

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
Published: May 29, 2009
Abstract Views: 177
PDF: 1196
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

MS Czuczman
support@pagepress.org
In recent years, the major approach to cancer therapy is rapidly moving away from the standard use of myelosuppressive combination chemotherapy regimens towards the testing and incorporation of more targeted therapies (e.g. monoclonal antibodies [mAbs], proteasome inhibition, anti-sense oligonucleotides, etc.). In general, these targeted therapies are associated with improved anti-tumor activity with significantly less non-specific toxicities. Nowhere is this evolution to more specific, less toxic therapy more apparent than in the field of non-Hodgkin’s lymphoma (NHL).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Czuczman, M. (2009). Anti-CD80 monoclonal antibody: galiximab. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.280
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).